Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Editorial

No regulatory double standard for natural health products

Noni E. MacDonald, Stuart MacLeod, Matthew B. Stanbrook, Paul C. Hébert, with editorial advisory team members, Ken Flegel and Daniel Rosenfield
CMAJ December 13, 2011 183 (18) 2079; DOI: https://doi.org/10.1503/cmaj.111739
Noni E. MacDonald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart MacLeod
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew B. Stanbrook
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul C. Hébert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Flegel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Rosenfield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Many consumers believe that natural health products are effective therapies and are safer than prescription drugs. This is oddly illogical reasoning. Although both appear to carry a similar Health Canada stamp of approval, there remains a specious dichotomy in the criteria and evidence needed for approval and monitoring of a drug compared with a natural health product.

Before marketing a substance as a drug, a pharmaceutical company must provide extensive evidence, typically from Phase III randomized controlled trials, that its product makes a quantifiable difference in a health condition and that the benefits outweigh the risks. The company must show that it has searched for common serious adverse events. All therapeutic claims are scrutinized, labelling is controlled and manufacturing standards are assured.

The same degrees of scrutiny, control and standardization do not apply to substances classified as natural health products or medicinal foods. This has created a loophole through which manufacturers can sell a product with implied health benefits without having to obtain the supporting scientific evidence that would be needed if it were sold as a drug. Nonmedical participants in the marketing chain seem all too willing to convey misinformation about the ostensible benefits of natural or other nondrug products. Problematic examples from just a single week’s recent news headlines include a skin cream claiming to make one slimmer,1 a fruit drink supplemented with potentially harmful levels of vitamin A,2 and caffeine and herbal extract–infused “energy” drinks, a category whose very name implies an unproven health effect.3

The multibillion-dollar natural health products industry sells the perception that because its products are “natural,” they must also be safe, such that comprehensive testing like that mandated for pharmaceuticals is not required. However, it is a near-universal truth that any substance that exerts a beneficial effect on a biological system will also have the potential for adverse effects. Therefore, any product truly free of adverse effects is likely to be inert.

Many natural products contain pharmacologically active compounds. Indeed, many of the oldest drugs evolved from herbal remedies to mainstream pharmaceutical products, including salicylates, opiates, curare, vincristine, colchicine, vitamins, quinine and digitalis, as well as more recent examples like artemisinin. Clearly, when a natural health product is truly efficacious, there are no obstacles to scientific validation. Why then should we accept a double standard of proof to allow thousands of such products to make health claims?

A decade ago, Health Canada created the Natural Health Products Directorate, establishing a regulatory framework that was a compromise between foods and drugs. But rather than ensuring safety, efficacy and quality, it has permitted products like the examples described here to be marketed with limited content labelling, poorly documented health benefits and little or no safety data. Consumer confusion has only increased as the number and types of natural health products have burgeoned and the lines between drugs and foods have become even more blurred.

Creating special categories for natural health products or medicinal foods is not the solution. Rather, all health claims for any product should be subject to a common set of regulations, starting with consistent and easily understood standards of evidence proportional to health risks and benefits. Regulatory evaluation should include a review of indications, clear labelling of health claims that an average consumer can understand, assurance of good manufacturing practices and a fulsome statement of product content. Postmarketing surveillance based on levels of potential risk must be in place to ensure that unanticipated adverse risks and serious drug interactions are detected.

Such regulations will add costs for government. However, just as with drugs, natural health products and medicinal foods should be assessed on a cost recovery basis. The high profit margins for many of these products should easily enable manufacturers to pay.

Uniform regulations are the best way to protect consumers while allowing choice. They will also ensure that health professionals have the necessary information about benefits, risks and quality to be able to counsel patients adequately about the health claims advertised for all products sold.

Footnotes

  • Competing interests: See www.cmaj.ca/site/misc/cmaj_staff.xhtml. Stuart MacLeod is a member of the Pediatric Expert Advisory Committee for Health Canada and has served as an advisor to the World Health Organization Better Medicines for Children Program. None declared for Paul Hébert.

References

  1. ↵
    1. Lu V
    . Nivea rapped a second time. Toronto Star 2011 Sept. 22. Available: www.thestar.com/business/article/1058029-nivea-rapped-a-second-time (accessed 2011 Oct. 14).
  2. ↵
    1. Schmidt S
    . Coca-Cola cuts vitamin A content in fruit beverage. Vancouver Sun 2011 Sept. 23. Available: www.vancouversun.com/health/Coca+Cola+cuts+vitamin+content+fruit+beverage/5446524/story.html#ixzz1algJY7bE (accessed 2011 Oct. 14).
  3. ↵
    1. Schmidt S
    . Energy drinks should only be sold under supervision of a pharmacist: Health Canada panel. National Post 2011 Sept. 20. Available: http://news.nationalpost.com/2011/09/20/energy-drinks-should-only-be-sold-under-supervision-of-a-pharmacist-health-canada-panel (accessed 2011 Oct. 14).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 183 (18)
CMAJ
Vol. 183, Issue 18
13 Dec 2011
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
No regulatory double standard for natural health products
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
No regulatory double standard for natural health products
Noni E. MacDonald, Stuart MacLeod, Matthew B. Stanbrook, Paul C. Hébert, with editorial advisory team members, Ken Flegel, Daniel Rosenfield
CMAJ Dec 2011, 183 (18) 2079; DOI: 10.1503/cmaj.111739

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
No regulatory double standard for natural health products
Noni E. MacDonald, Stuart MacLeod, Matthew B. Stanbrook, Paul C. Hébert, with editorial advisory team members, Ken Flegel, Daniel Rosenfield
CMAJ Dec 2011, 183 (18) 2079; DOI: 10.1503/cmaj.111739
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Take turmeric with a grain of salt
  • Enforcement of natural health product regulations
  • Google Scholar

More in this TOC Section

  • Le sujet de l’heure : l’accès aux soins de santé au Canada
  • Integration of midwifery care in Canada
  • CMAJ’s new guidance on the reporting of race and ethnicity in research articles
Show more Éditorial

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire